{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:05:44Z","timestamp":1790741144063,"version":"4.1.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U01HL123336"],"award-info":[{"award-number":["U01HL123336"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1UG3HL164285"],"award-info":[{"award-number":["1UG3HL164285"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01HL169015"],"award-info":[{"award-number":["R01HL169015"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000659","name":"Clinical Coordinating Center","doi-asserted-by":"publisher","award":["U01HL123339"],"award-info":[{"award-number":["U01HL123339"]}],"id":[{"id":"10.13039\/501100000659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000659","name":"Clinical Coordinating Center","doi-asserted-by":"publisher","award":["1U24HL164284"],"award-info":[{"award-number":["1U24HL164284"]}],"id":[{"id":"10.13039\/501100000659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Data Coordinating Center"},{"DOI":"10.13039\/100001797","name":"Kowa Pharmaceuticals America, Inc.","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001797","name":"Kowa Pharmaceuticals America, Inc.","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016862","name":"ACTG Laboratory Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018644","name":"Boston Nutrition Obesity Research Center","doi-asserted-by":"publisher","award":["P30DK040561"],"award-info":[{"award-number":["P30DK040561"]}],"id":[{"id":"10.13039\/100018644","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>REPRIEVE findings catalyzed changes to multiple guidelines directing statin therapy prescribing for people with HIV (PWH). US guidelines use the pooled cohort equation (PCE)-derived 10-year atherosclerotic cardiovascular disease (ASCVD) risk score but may in the future incorporate the new Predicting Risk of CVD EVENTs (PREVENT) score. Meanwhile, European guidelines use Systematic Coronary Risk Evaluation 2 (SCORE2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Leveraging Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), we compared effects of applying PCE versus either PREVENT according to US guidelines or SCORE2 according to European guidelines among a global primary CVD prevention cohort of PWH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis cohort included 7757 participants with data for PREVENT and SCORE2 calculation. Ten-year ASCVD risk estimates (median [Q1, Q3]) were highest with PCE (4.4% [2.1%, 7.1%]) versus SCORE2 (3.3% [2.0%, 4.9%]) and PREVENT (2.2% [1.3%, 3.3%]). PREVENT- (vs PCE-) based scoring reclassified 38% of participants from a higher to a lower risk group (\u22655% to &amp;lt;5%), while SCORE2-based scoring analogously shifted 27% of those age \u226550 years. Among placebo-assigned participants, median observed incidence of hard major adverse cardiovascular events (MACEs)\/1000 person-years (PY) was higher than that predicted by PREVENT, except for those with ultralow predicted risk. The estimated cumulative incidence of primary MACE was higher and 5-year number needed to treat (NNT5) lower for most risk groups using PREVENT versus PCE. The NNT5 for the PREVENT-defined risk group of 2.5\u20135.0% was close to the NNT5 for the PCE-defined risk group of \u22655% (NNT5[95% CI]: 53 [31, 178] vs 47 [30, 109], respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Statin-prescribing guidelines for PWH based on REPRIEVE should account for differences in 10-year ASCVD risk estimates when scores other than PCE are used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>National Institutes of Health, Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare<\/jats:p>\n                    <jats:p>Clinical Trials Registration. REPRIEVE; NCT02344290; https:\/\/clinicaltrials.gov\/study\/NCT02344290.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf542","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:03:44Z","timestamp":1758801824000},"page":"e248-e257","source":"Crossref","is-referenced-by-count":8,"title":["Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2"],"prefix":"10.1093","volume":"82","author":[{"given":"Steven K","family":"Grinspoon","sequence":"first","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5828-0706","authenticated-orcid":false,"given":"Sophia","family":"Zhao","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"The Infectious Diseases Service, Hospital Clinic and University of Barcelona , Barcelona ,","place":["Spain"]},{"name":"CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J","family":"Fichtenbaum","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Cincinnati College of Medicine , Cincinnati, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Chu","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa R","family":"Diggs","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7161-7743","authenticated-orcid":false,"given":"Triin","family":"Umbleja","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0289-1295","authenticated-orcid":false,"given":"Sara","family":"McCallum","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0541-3707","authenticated-orcid":false,"given":"Kathleen V","family":"Fitch","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia A","family":"Triant","sequence":"additional","affiliation":[{"name":"Division of General Medicine, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4279-4737","authenticated-orcid":false,"given":"Judith S","family":"Currier","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A","family":"Aberg","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-2965","authenticated-orcid":false,"given":"Carlos D","family":"Malvestutto","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Ohio State University Medical Center , Columbus, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0808-6729","authenticated-orcid":false,"given":"Kristine M","family":"Erlandson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado\u2014Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald S","family":"Bloomfield","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke Global Health Institute and Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T","family":"Lu","sequence":"additional","affiliation":[{"name":"Cardiovascular Imaging Research Center, Department of Radiology and Department of Cardiology, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S","family":"Douglas","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-3990","authenticated-orcid":false,"given":"Heather J","family":"Ribaudo","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markella V","family":"Zanni","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Massachusetts General Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"2026031306473840800_ciaf542-B1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"2026031306473840800_ciaf542-B2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"2026031306473840800_ciaf542-B3","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMc2400870","article-title":"Trial update of pitavastatin to prevent cardiovascular events in HIV infection","volume":"390","author":"Grinspoon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026031306473840800_ciaf542-B4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ahj.2018.12.016","article-title":"Rationale and design of the randomized trial to prevent vascular events in HIV (REPRIEVE)","volume":"212","author":"Grinspoon","year":"2019","journal-title":"Am Heart J"},{"key":"2026031306473840800_ciaf542-B5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"2026031306473840800_ciaf542-B6","author":"US Department of Health and Human Services"},{"key":"2026031306473840800_ciaf542-B7","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7326\/ANNALS-24-03564","article-title":"Statin therapy as primary prevention for persons with HIV: a synopsis of recommendations from the U.S. Department of health and human services antiretroviral treatment guidelines panel","volume":"178","author":"Beavers","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026031306473840800_ciaf542-B8","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1016\/S2352-3018(24)00276-5","article-title":"Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE","volume":"12","author":"Grinspoon","year":"2025","journal-title":"Lancet HIV"},{"key":"2026031306473840800_ciaf542-B9","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"2026031306473840800_ciaf542-B10","doi-asserted-by":"crossref","first-page":"e382","DOI":"10.1016\/S2352-3018(25)00047-5","article-title":"Statin use in HIV: European AIDS clinical society guidance for the primary prevention of cardiovascular disease","volume":"12","author":"Alagaratnam","year":"2025","journal-title":"Lancet HIV"},{"key":"2026031306473840800_ciaf542-B11","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamainternmed.2024.1302","article-title":"Atherosclerotic cardiovascular disease risk estimates using the predicting risk of cardiovascular disease events equations","volume":"184","author":"Anderson","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026031306473840800_ciaf542-B12","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/ajhp\/zxac224","article-title":"Underprescribing of statin therapy in people with HIV at risk for atherosclerotic cardiovascular disease","volume":"79","author":"Gallegos Aragon","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"2026031306473840800_ciaf542-B13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s15010-016-0893-z","article-title":"Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study","volume":"44","author":"De Socio","year":"2016","journal-title":"Infection"},{"key":"2026031306473840800_ciaf542-B14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jama.2024.12537","article-title":"Projected changes in statin and antihypertensive therapy eligibility with the AHA PREVENT cardiovascular risk equations","volume":"332","author":"Diao","year":"2024","journal-title":"JAMA"},{"key":"2026031306473840800_ciaf542-B15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"2026031306473840800_ciaf542-B16","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"SCORE2 Working Group and ESC Cardiovascular Risk Collaboration","year":"2021","journal-title":"Eur Heart J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf542\/64416181\/ciaf542.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/2\/e248\/64416181\/ciaf542.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/2\/e248\/64416181\/ciaf542.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T10:47:47Z","timestamp":1773398867000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/2\/e248\/8266567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,26]]},"published-print":{"date-parts":[[2026,2,25]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf542","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,15]]},"published":{"date-parts":[[2025,9,26]]}}}